BioVie Receives Notice Of Allowance For Japan Patent Application Covering Novel Liquid Formulation Of Terlipressin
Portfolio Pulse from Benzinga Newsdesk
BioVie Inc. has received a Notice of Allowance from the Japan Patent Office for its novel liquid formulation of terlipressin, which is stable at room temperature for up to 24 months. This patent adds to BioVie's existing patents in the US, India, and Chile, and supports the development of a patient-centric treatment for cirrhosis and ascites.
October 15, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie Inc. has secured a Notice of Allowance for a Japanese patent on its novel liquid formulation of terlipressin, which is stable at room temperature for 24 months. This strengthens BioVie's intellectual property portfolio and supports its development of treatments for cirrhosis and ascites.
The Notice of Allowance for a Japanese patent strengthens BioVie's intellectual property portfolio, which is crucial for protecting its novel formulation of terlipressin. This development supports BioVie's strategy to offer a stable, patient-friendly treatment for cirrhosis and ascites, potentially increasing its market presence and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100